Cancer

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as HNF4α, PP2A, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 20/June/2019, 7.33 am
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as HNF4α, PP2A, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 20/June/2019, 7.33 am 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research paper was published, in…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BIRC5, p12DOC1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 17/June/2019, 6.14 am
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BIRC5, p12DOC1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 17/June/2019, 6.14 am 1280 720 Dr Boomi's Genom-2-Discovery Center

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SMARCA4, KIBRA, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 17/June/2019, 5.48 am
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SMARCA4, KIBRA, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 17/June/2019, 5.48 am 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research paper was published, in…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BIRC5, PIAS3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 13/June/2019, 10.26 pm
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BIRC5, PIAS3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 13/June/2019, 10.26 pm 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research paper was published, in…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TIMP3, PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 09/June/2019, 6.23 pm
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TIMP3, PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 09/June/2019, 6.23 pm 1280 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research paper was published, in…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 05/June/2019, `7.17 am
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 05/June/2019, `7.17 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research paper was published, in…

read more
Start Typing